# Gene Editing * **Definition:** A technique that allows scientists to modify an organism's DNA with high precision, potentially correcting genetic defects or treating diseases, often utilizing technologies such as CRISPR-Cas9. * **Taxonomy:** Healthcare Topics / Gene Editing ## News * Selected news on the topic of **Gene Editing**, for healthcare technology leaders * 10K news items are in the system for this topic * Posts have been filtered for tech and healthcare-related keywords | Date | Title | Source | | --- | --- | --- | | 5/27/2025 | [**Gene editing leaders call for 10-year suspension of heritable human genome editing**](https://www.fiercebiotech.com/research/gene-editing-leaders-call-10-year-suspension-heritable-human-genome-editing) | [[FierceBiotech]] | | 5/16/2025 | [**Gene editing helped a desperately ill baby thrive. Scientists say it could someday treat millions**](https://www.aol.com/gene-editing-helped-desperately-ill-174905210.html) | [[AOL]] | | 5/15/2025 | [**Customized CRISPR gene editing therapy successfully treats infant with rare disease**](https://www.news-medical.net/news/20250515/Customized-CRISPR-gene-editing-therapy-successfully-treats-infant-with-rare-disease.aspx) | [[News Medical Net]] | | 5/15/2025 | [**World's First Patient Treated with Personalized CRISPR Gene Editing Therapy at Children's ...**](https://www.prnewswire.com/news-releases/worlds-first-patient-treated-with-personalized-crispr-gene-editing-therapy-at-childrens-hospital-of-philadelphia-302457039.html) | [[PR Newswire]] | | 5/9/2025 | [**Precision Medicine Market Analysis Report 2024-2030: Bristol-Myers Squibb, Illumina ...**](https://finance.yahoo.com/news/precision-medicine-market-analysis-report-131300143.html) | [[Yahoo Finance]] | | 4/23/2025 | [**CRISPR Gene Editing Market Forecast: Demand, nsights 2027**](http://prsync.com/markntel-advisors/crispr-gene-editing-market-forecast-demand--player-insights--4725416/) | [[PRSync]] | | 3/10/2025 | [**ElevateBio Collaborates with AWS to Broaden the Potential of CRISPR Gene Editing ...**](https://www.morningstar.com/news/globe-newswire/9389883/elevatebio-collaborates-with-aws-to-broaden-the-potential-of-crispr-gene-editing-therapies-with-generative-ai) | [[Morningstar]] | | 3/9/2025 | [**ElevateBio Collaborates with AWS to Broaden the Potential of CRISPR Gene Editing Therapies with Generative AI**](https://markets.businessinsider.com/news/stocks/elevatebio-collaborates-with-aws-to-broaden-the-potential-of-crispr-gene-editing-therapies-with-generative-ai-1034458434) | [[Business Insider Markets]] | | 3/7/2025 | [**The Future of Biotechnology: Medical, Food Technology, and Bioinformatics Innovations**](https://medium.com/@sourabh.more_60784/the-future-of-biotechnology-medical-food-technology-and-bioinformatics-innovations-37c067197fbb) | [[Medium]] | | 3/6/2025 | [**Gene Editing Collaboration and Licensing Terms and Agreements Trends Report ... - Yahoo Finance**](https://finance.yahoo.com/news/gene-editing-collaboration-licensing-terms-160700470.html) | [[Yahoo Finance]] | | 1/31/2025 | [**Biotech Market to Grow by USD 805.6 Billion (2025-2029), Boosted by Vendor Innovation ...**](https://www.prnewswire.com/news-releases/biotech-market-to-grow-by-usd-805-6-billion-2025-2029-boosted-by-vendor-innovation-with-ai-driving-market-transformation---technavio-302364467.html) | [[PR Newswire]] | | 1/28/2025 | [**Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs**](https://finance.yahoo.com/news/precision-biosciences-strengthens-senior-leadership-120100438.html) | [[Yahoo Finance]] | | 1/1/2025 | [**4 companies to watch in the accelerating gene editing race**](https://finance.yahoo.com/news/4-companies-watch-accelerating-gene-070254968.html) | [[Yahoo Finance]] | | 12/30/2024 | [**Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In?**](https://finance.yahoo.com/news/why-editas-medicine-inc-edit-201112515.html) | [[Yahoo Finance]] | | 11/29/2024 | [**Gene Editing Market Forecast Report 2024, with Profiles of Merck, GenScript, Revvity, Lonza ...**](https://finance.yahoo.com/news/gene-editing-market-forecast-report-094300285.html) | [[Yahoo Finance]] | | 11/27/2024 | [**Gene Editing Market: Key Growth Drivers, Trends, and Future Prospects in Biotechnology**](http://prsync.com/maximize-market-research---hc/gene-editing-market-key-growth-drivers-trends-and-future-prospects-in-biotechnology-4460053/) | [[PRSync]] | | 11/18/2024 | [**CF Foundation Invests Up to $15 million in ReCode Therapeutics to Develop a Gene Editing Therapy**](https://finance.yahoo.com/news/cf-foundation-invests-15-million-130000027.html) | [[Yahoo Finance]] | | 11/15/2024 | [**Gene Editing Market to Hit USD 7.59 Billion by 2029 with 10.2AGR - MarketsandMarkets™**](https://www.prnewswire.com/news-releases/gene-editing-market-to-hit-usd-7-59-billion-by-2029-with-10-2-cagr--marketsandmarkets-302306841.html) | [[PR Newswire]] | | 10/28/2024 | [**Researchers discover underlying mechanisms that make CRISPR an effective gene editing tool**](https://phys.org/news/2024-10-underlying-mechanisms-crispr-effective-gene.html) | [[Phys Org]] | | 10/28/2024 | [**Researchers uncover key mechanisms of CRISPR gene editing**](https://www.news-medical.net/news/20241028/Researchers-uncover-key-mechanisms-of-CRISPR-gene-editing.aspx) | [[News Medical Net]] | | 8/21/2024 | [**Gene Editing Market Competitor Analysis: Opportunities and Challenges**](http://prsync.com/marketsandmarkets---hc/gene-editing-market-competitor-analysis-opportunities-and-challenges-4251158/) | [[PRSync]] | | 8/12/2024 | [**Gene Editing Market Strategic Insights: Growth Opportunities**](http://prsync.com/marketsandmarkets---hc/gene-editing-market-strategic-insights-growth-opportunities-4241204/) | [[PRSync]] | | 8/8/2024 | [**CRISPR Gene Editing Market Forecasted to Reach New Heights by 2033 and In-Depth ...**](https://www.whatech.com/og/markets-research/medical/864648-crispr-gene-editing-market-forecasted-to-reach-new-heights-by-2033-and-in-depth-market-analysis.html) | whatech.com | | 7/8/2024 | [**Global Gene Editing Partnering Deals Analysis Report and Directory 2016-2024: Collaboration, Development, Research and Licensing Deals by Company A-Z, Deal Type and Therapy Area - ResearchAndMarkets.com**](http://www.businesswire.com/news/home/20240708658315/en/Global-Gene-Editing-Partnering-Deals-Analysis-Report-and-Directory-2016-2024-Collaboration-Development-Research-and-Licensing-Deals-by-Company-A-Z-Deal-Type-and-Therapy-Area---ResearchAndMarkets.com/?feedref=JjAwJuNHiystnCoBq_hl-RLXHJgazfQJNuOVHefdHP-D8R-QU5o2AvY8bhI9uvWSD8DYIYv4TIC1g1u0AKcacnnViVjtb72bOP4-4nHK5ieT3WxPE8m_kWI77F87CseT) | [[Business Wire]] | | 6/24/2024 | [**Study shows familiarity with gene editing increases approval of the safety of GMOs**](https://phys.org/news/2024-06-familiarity-gene-safety-gmos.html) | [[Phys Org]] | ## Topic Overview (Some LLM-derived content — please confirm with above primary sources) ### Key Players - **Metagenomi, Inc.**: A company specializing in gene editing tools, including adenine base editors and programmable nucleases, aimed at correcting genetic mutations. - **Editas Medicine**: A biotechnology firm focusing on in-vivo gene editing therapies, recently shifting its strategy to enhance its gene editing capabilities. - **Precision BioSciences**: Developed the ARCUS platform for high-efficiency gene editing. - **Merck KGaA**: Involved in advancing gene editing technologies and synthetic biology applications. - **Crispr Therapeutics**: A leading player in gene editing, known for its Casgevy therapy, which has received FDA approval. - **University of Sydney**: Created SeekRNA, a new gene-editing tool with improved accuracy and flexibility. - **SOHM, Inc.**: A company advancing gene editing technologies, recently receiving a patent for its ABBIE gene editing technology aimed at therapeutic applications. - **Mammoth Biosciences**: Develops ultracompact CRISPR systems for in vivo gene editing. - **YolTech Therapeutics**: Focuses on gene editing therapies for genetic blood disorders. - **Vertex Pharmaceuticals**: A seasoned biotech firm collaborating with Crispr Therapeutics on gene editing therapies. ### Partnerships and Collaborations - **Broken String Biosciences Catalyst Program**: An initiative to enable developers of gene-edited therapies to detect on- and off-target edits quickly. - **Editas Medicine and Genevant Sciences**: Collaboration to develop in vivo gene editing medicines using CRISPR Cas12a and lipid nanoparticle technology. - **Metagenomi and Ionis**: Collaborating to develop gene editing candidates for cardiometabolic indications, with plans to nominate candidates by 2025. - **Corteva and Pairwise**: A strategic collaboration to deliver advanced gene editing solutions in agriculture. - **Vertex Pharmaceuticals and CRISPR Therapeutics**: Collaboration leading to the FDA approval of Casgevy, a gene editing therapy for sickle cell disease and beta thalassemia. - **ElevateBio and AWS**: A multi-year collaboration to enhance CRISPR gene editing therapeutics using generative AI. - **Tome Biosciences and Genevant Sciences**: Partnership to develop gene editing therapies for liver disorders. - **YolTech and KACTUS**: Partnership to commercialize YolCas12TM gene editing technology in Greater China. - **ERS Genomics and Université de Montréal**: A non-exclusive CRISPR/Cas9 license agreement to enhance research capabilities. - **ReCode and Intellia Therapeutics**: Collaborating on gene editing therapy targeting lung cells affected by cystic fibrosis. - **SOHM and an undisclosed partner**: A collaboration to develop microfluidic-based gene editing technology for CAR-T cell therapies. - **Vertex Pharmaceuticals and Orna Therapeutics**: Partnership to utilize lipid nanoparticle technology for improved delivery of gene editing therapies. - **Cystic Fibrosis Foundation and ReCode Therapeutics**: Investing up to $15 million to support gene editing therapy development for cystic fibrosis. - **Intellia Therapeutics and ReCode Therapeutics**: Collaboration to develop gene editing therapies targeting cystic fibrosis. - **Celltech Innovation Venture Studio and Minaris Regenerative Medicine**: Partnered to enhance regenerative medicine growth in the cell and gene therapy sector. - **DNAnexus and Discovery Life Sciences**: Partnership aimed at enhancing AI-driven solutions and improving precision health data analysis. - **Children's Hospital of Philadelphia and University of Pennsylvania**: Collaborated on a groundbreaking gene therapy model for X-linked sideroblastic anemia. - **George Mason University and Inova Health Systems**: Collaboration to house a biobank for public health research, enhancing genetic research capabilities. ### Innovations, Trends, and Initiatives - **Prime Editing**: A new gene-editing technique that allows for precise genetic modifications without double-stranded breaks, showing promise in treating cystic fibrosis. - **Bridge RNA Technology**: New gene editing technique allowing for versatile DNA modifications. - **CRISPR and Gene Editing Technologies**: Advancements in CRISPR, base editing, and prime editing are set to revolutionize genetics and therapeutic applications. - **Emerging Techniques**: Innovations such as prime editing and bridge RNA are enhancing gene editing capabilities. - **Gene editing for cancer**: Research at ChristianaCare's Gene Editing Institute targeting melanoma treatment resistance. - **CRISPR-Cas9 Technology**: Revolutionizing gene editing with precise DNA modifications, leading to potential treatments for genetic disorders. - **In Vivo Gene Editing**: Vertex exploring direct editing of stem cells within the body to enhance treatment efficiency. - **In vivo gene editing**: Editas Medicine's shift towards in vivo therapies for genetic disorders. - **Gene Editing Stocks Trend**: Investing in gene editing stocks is emerging as a significant trend in biopharma, with potential for long-term returns. - **Gene Editing Market Growth**: Projected to grow from USD 4.66 billion in 2024 to USD 7.59 billion by 2029, driven by personalized medicine demand and government funding. - **CRISPR-Cas9**: A revolutionary gene editing technology that allows for precise modifications in DNA, significantly impacting drug development and personalized medicine. - **STITCHR**: A novel RNA-based gene editing tool developed by researchers at Mass General Brigham, allowing for precise insertion of therapeutic genes. - **AI in Gene Editing**: AI is being utilized to optimize gene editing processes and enhance the understanding of protein structures. - **Compact genome editing tools**: Metagenomi's development of smaller CRISPR systems for enhanced delivery. - **SeekRNA**: Programmable RNA strand tool for precise gene editing. - **Adenine Base Editors (ABE)**: Developed by Metagenomi, these tools demonstrate high specificity and no detectable off-target effects, enhancing the safety of gene editing therapies. - **Delivery Mechanisms**: Innovations in lipid nanoparticles and viral vectors are improving the effectiveness of gene editing. - **AI in CRISPR**: AI applications in CRISPR gene editing enhance precision and minimize off-target effects. - **CRISPR Technology**: Utilization of CRISPR/Cas9 for gene editing therapies, with ongoing developments to simplify treatment processes. ### Challenges and Concerns - **Off-Target Effects**: Precision in gene editing is crucial to avoid unintended edits that could lead to harmful consequences, including cancer. - **Ethical Concerns**: Gene editing raises ethical questions regarding genetic modifications in humans. - **Ethical and Regulatory Issues**: Concerns regarding genetic manipulation and the implications of gene editing technologies. - **Ethical considerations**: The ethical implications of gene editing technologies, particularly in human applications. - **Unintended Genetic Changes**: Research indicates potential for significant unintended genetic alterations from gene editing, necessitating further study. - **Ethical Considerations**: Concerns regarding the ethical implications of gene editing, particularly in human applications and potential long-term effects. - **Public perception**: Concerns regarding the acceptance of gene editing technologies in society. - **Public Perception**: Concerns about the safety and long-term effects of gene editing technologies. - **Cost of Technology**: High costs associated with advanced gene editing technologies can limit accessibility and widespread adoption. - **Regulatory hurdles**: Challenges in navigating regulatory frameworks for gene editing therapies. - **High Costs of Technology**: The costs associated with gene editing technologies, including specialized equipment and reagents, pose challenges for widespread adoption. - **Regulatory Hurdles**: Navigating regulatory frameworks for gene editing therapies can be complex. - **Regulatory Challenges**: Navigating the regulatory landscape for gene editing therapies remains complex and challenging. ## Related Topics [[Genome Editing]]; [[Gene Therapy]]